Also In This Special Report
Part 1
Daniel C. McFarland, DO; Luigi Grassi, MD; Michelle Riba, MD, MS, DFAPA, FAPM
Steve Adelman, MD
Chris Aiken, MD
Part 2
Research Roundup: Psychiatric Comorbidities in the News
Leah Kuntz and Erin O’Brien
30% to 60% of individuals seeking treatment for SUD also meet criteria for PTSD.
SPECIAL REPORT: COMORBIDITIES PART 2
The experience of
Daniel C. McFarland, DO; Luigi Grassi, MD; Michelle Riba, MD, MS, DFAPA, FAPM
Steve Adelman, MD
Chris Aiken, MD
Research Roundup: Psychiatric Comorbidities in the News
Leah Kuntz and Erin O’Brien
Evidence-based treatments exist for both PTSD and SUD; however, the approaches are rarely integrated, despite recognition of frequent cooccurrence. There are trends to further integrate
Treatment of SMI-related distress or symptomatology in isolation from SUD fails to address the whole person and is likely to result in suboptimal outcomes.7 Without integration of SUD and SMI care, providers risk inappropriately generalizing diagnoses without recognizing the context and lens of SMI symptoms. Addressing an epidemic requires the responsiveness of all providers.8 As SUD services, treatment, and research have advanced, we highlight 5 practices that are useful in supporting psychiatric clinicians as they effectively integrate trauma-informed SUD and SMI treatment.
Integrate TIC and Substance Use Care
There is substantial evidence that clinicians do not routinely ask patients about trauma history in clinical settings.1 Despite growing recognition of the impact of adverse childhood experiences on individuals and awareness of trauma prevalence, both institutional and intrinsic barriers interfere with provider inquiries about
Similarly, inquiring about substance use and recurrence of substance use must be an ongoing practice. Patients may not disclose substance use right away for a multitude of reasons. As the provider learns this information, the trajectory of care may change, much like when we are asking about trauma. Assessment around SUD also requires being trauma-informed, as increased
Recognize Trauma as a Primary Pathway to Substance Use
For decades, the pervasive narrative around
Drug use sequences and initiation vary based on cultural context and on unmeasured common causes that are understood to be more impactful on subsequent drug use than initial use of a particular substance.12 There is clearly an association between experiences of trauma and
One notable evidence-based approach is integrated treatment for cooccurring disorders (ITCOD). Integrating treatment approaches for mental illness and SUDs requires looking at combining efficacious existing treatments while modifying interventions that may be outdated or lack reliable benefit.2 ITCOD is a multifaceted approach to treatment and care that captures the importance of individual therapy, assertive outreach, social support interventions, and long-range perspective via a patient-centered framework.2
As we unlearn the non–evidence-based “gateway hypothesis,” a deeper dive into traumatic experiences and their relation to substance use is likely to serve both provider and patient. Often, substance use initiation is related to seeking relief from pain as well as traumatic events and symptoms.14 Providers can more fully explore events preceding substance use initiation or transition to nonprescribed medication with compassionate understanding, recognizing that
When we sit in the office with a 40-year-old patient, for example, imagine, as they are sharing memories of their traumatic upbringing with you, that they are 12 years old and not in your office, but in their home—terrified of the trauma there. They have no resources or outlets. A substance is introduced, and it temporarily provides some relief of the awful feelings that they are experiencing. That is not a moral weakness or deficiency. One can imagine what one would do in that situation, but the context and the patient’s experience are of utmost importance, and we need to remove our own opinions from the equation. Intergenerational trauma is another prevalent reality, and the cycle perpetuates. When someone comes to see us for help, it is our job to use our expertise and understanding to facilitate their healing and
Partner With Patients Across Multiple Pathways to Recovery
Substance-specific 12-step programs like Alcoholics Anonymous (AA) and Narcotics Anonymous are often considered synonymous with peer-led recovery. These programs have benefited millions of people over the course of decades. However, these models are based on an abstinence-only philosophy with religious/spiritual elements, wherein sobriety is the explicit goal for group members. These programs have provided effective support for countless individuals and families, but they do not fit all people seeking or maintaining recovery.
Abstinence-only models are not a panacea. Many individuals suffering from SUD are not able or ready to totally discontinue use or are turned off by the religious basis of these groups, resulting in disengagement from these services.15 Alternatives to spiritually based and abstinence-only peer-led mutual support groups exist and should be considered viable recovery pathways for patients. They include SMART Recovery, Secular Organizations for Sobriety, Moderation Management, LifeRing, Women for Sobriety, and Celebrate Recovery, among others.16 In addition to these peer-led groups, harm reduction services—including peer-led groups and/or syringe services programs—can be a critical low-barrier access point to engage patients with SUD who are not interested in abstinence. Abstinence and
Instead of referring patients to treatments that are not well suited to the individual, acknowledging the multiple pathways to treatment and recovery is imperative. We have heard of the challenging routes patients have faced on their journey to treatment and recovery, such as a provider telling them they could not be seen “until they go to AA and stop drinking.” This advice is as good as telling your patient to leave your office and never come back again. Supporting multiple pathways helps meet patients where they are, learn where patients are in their willingness to engage in treatment, and determine which modalities may be the best fit for them. It is important to engage in a shared decision-making process and provide options, rather than providing a paternalistic recommendation that does not take patient preference or prior experiences into consideration.
Approach With Unconditional Positive Regard
When assessing patients, the longstanding OLDCARTS (onset, location/radiation, duration, character, aggravating factors, relieving factors, timing, severity) acronym utilized in general medicine can be adapted for psychiatric evaluation and assessment. Information gathering in a psychiatric evaluation is not a rigid, linear, “checking off the boxes” process—there is, of course, an
Approaching our patients from a place of unconditional positive regard, a concept expanded upon by Carl Rogers, is central to facilitating a safe space for our patients to share with us what is going on without judgment, and without fear of disappointing us as providers. Our interactions with patients are timebound, limited, and within a physical space most often that is “our” home turf: our office space.
Ongoing self-reflection and assessing areas of one’s own implicit biases are imperative. A systematic review looking at health care professionals’ attitudes toward patients with SUDs found negative attitudes toward this patient population, which impacted patient outcomes unfavorably.18 There are often inciting events for these views, and the outward expression is likely most often unintentional. As lifelong learners, we are well served to recognize when inaccurate conceptualizations (eg, the gateway hypothesis) have led us astray in oversimplifying substance use within our visits.
Engage in Ongoing Knowledge and Skill Development
A systematic review of negative provider views impacting patient outcomes identifies needs for education, training, and improved structure to better support complex patients.18 Formal educational opportunities including fellowships in
There are peer-facilitated learning opportunities, as well as the PACT-MAT ECHO model,20 which is an all-teach, all-learn approach. These sessions have many benefits, especially since comorbidity of a psychiatric disorder along with a SUD is often an area where clinicians appreciate feedback and recommendations for ongoing care. It is also an excellent opportunity to network and for clinicians to become familiar with other area resources and referral locations.
Concluding Thoughts
As psychiatric care providers amid a challenging health care landscape and a global pandemic, we are tasked with providing optimal care to our patients and meeting their needs. The evidence, as we have noted, continues to evolve, and this provides all of us with the opportunity to self-reflect and continue adapting in our own practice and methods. Opportunities for collaboration and growing our knowledge base abound, and within the field we are lucky to have colleagues and mentors to support us along this journey.
Mrs Robinson is a psychiatric-mental health nurse practitioner in the Seacoast, New Hampshire, area, and a clinical assistant professor and program director of the Post-Masters Psychiatric-Mental Health Nurse Practitioner Certificate Program, Department of Nursing, University of New Hampshire, Durham. Ms Apicelli serves as the project manager for the Harm Reduction Education and Technical Assistance project, a multiorganization collaboration dedicated to reducing drug-related harms, based at the Department of Nursing, University of New Hampshire. She is also an adjunct professor in the university’s Department of Social Work. Dr Nolte is a family nurse practitioner in community health and an assistant professor of nursing at the University of New Hampshire. Dr Nolte’s research focus is reducing drug-related harms.
References
1. Coyle L, Hanna D, Dyer KFW, et al.
2. Integrated treatment for co-occurring disorders. Substance Abuse and Mental Health Services Administration. 2009. Accessed January 7, 2022.
3. Rasmussen IS, Arefjord K, Winje D, Dovran A.
4. Mihelicova M, Brown M, Shuman V.
5. Beckett P, Holmes D, Phipps M, et al.
6. Pfefferbaum B, North CS.
7. Chessen CE, Comtois KA, Landes SJ.
8. Brunette MF, Oslin DW, Dixon LB, et al.
9. McCauley JL, Killeen T, Gros DF, et al.
10. Nöel W, Wang J. Is cannabis a gateway drug? Key findings and literature review. National Institute of Justice. 2018. Accessed January 7, 2022.
11. Bradford AC, Bradford WD, Abraham A, Bagwell Adams G.
12. Degenhardt L, Dierker L, Chiu WT, et al.
13. Nolte K, Drew AL, Friedmann PD, et al.
14. Lederhos Smith C, Severtsen B, Vandermause R, et al.
15. Henwood BF, Padgett DK, Tiderington E.
16. Kelly JF, White WL.
17. Carver H, Ring N, Miler J, Parkes T.
18. van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL.
19. Galanter M.
20. Salvador J, Bhatt S, Fowler R, et al.
over 3 years ago
Research Roundup: Psychiatric Comorbidities in the Newsover 3 years ago
Best Recent Screen Portrayals of Mental Health Issuesover 3 years ago
Chronic Kidney Disease and Lithium—A New Perspectiveover 3 years ago
Optogenetics and Piercing the Professional Armorover 3 years ago
“Inappropriate” Consults: Taxonomy and Strategyover 3 years ago
Exploring Antipsychotic Dose-Responseover 3 years ago
The Assessment of Depression Among Older Adultsover 3 years ago
DSM-5-TR…Already?Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.